PURPOSE: To retrospectively evaluate safety and effectiveness of CT-guided percutaneous microwave ablation (MWA) in 47 patients with medically inoperable stage I peripheral non-small cell lung cancer (NSCLC). METHODS: From February 2008 to October 2012, 47 patients with stage I medically inoperable NSCLC were treated in 47 MWA sessions. The clinical outcomes were evaluated. Complications after MWA were also summarized. RESULTS: At a median follow-up period of 30 months, the median time to the first recurrence was 45.5 months. The local control rates at 1, 3, 5 years after MWA were 96%, 64%, and 48%, respectively. The median cancer-specific and median overall survivals were 47.4 and 33.8 months. The overall survival rates at 1, 2, 3, and 5 years after MWA were 89%, 63%, 43%, and 16%, respectively. Tumors ≤3.5 cm were associated with better survival than were tumors >3.5 cm. The complications after MWA included pneumothorax (63.8%), hemoptysis (31.9%), pleural effusion (34%), pulmonary infection (14.9%), and bronchopleural fistula (2.1%). CONCLUSIONS: MWA is safe and effective for the treatment of medically inoperable stage I peripheral NSCLC.
PURPOSE: To retrospectively evaluate safety and effectiveness of CT-guided percutaneous microwave ablation (MWA) in 47 patients with medically inoperable stage I peripheral non-small cell lung cancer (NSCLC). METHODS: From February 2008 to October 2012, 47 patients with stage I medically inoperable NSCLC were treated in 47 MWA sessions. The clinical outcomes were evaluated. Complications after MWA were also summarized. RESULTS: At a median follow-up period of 30 months, the median time to the first recurrence was 45.5 months. The local control rates at 1, 3, 5 years after MWA were 96%, 64%, and 48%, respectively. The median cancer-specific and median overall survivals were 47.4 and 33.8 months. The overall survival rates at 1, 2, 3, and 5 years after MWA were 89%, 63%, 43%, and 16%, respectively. Tumors ≤3.5 cm were associated with better survival than were tumors >3.5 cm. The complications after MWA included pneumothorax (63.8%), hemoptysis (31.9%), pleural effusion (34%), pulmonary infection (14.9%), and bronchopleural fistula (2.1%). CONCLUSIONS:MWA is safe and effective for the treatment of medically inoperable stage I peripheral NSCLC.
Authors: S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman Journal: Radiology Date: 2005-04-21 Impact factor: 11.105
Authors: Damian E Dupuy; Thomas DiPetrillo; Sachin Gandhi; Neal Ready; Thomas Ng; Walter Donat; William W Mayo-Smith Journal: Chest Date: 2006-03 Impact factor: 9.410
Authors: Luis J Herrera; Hiran C Fernando; Yaron Perry; William E Gooding; Percival O Buenaventura; Neil A Christie; James D Luketich Journal: J Thorac Cardiovasc Surg Date: 2003-04 Impact factor: 5.209
Authors: Farrah J Wolf; David J Grand; Jason T Machan; Thomas A Dipetrillo; William W Mayo-Smith; Damian E Dupuy Journal: Radiology Date: 2008-03-27 Impact factor: 11.105
Authors: Cheng S Jin; Hironobu Wada; Takashi Anayama; Patrick Z McVeigh; Hsin Pei Hu; Kentaro Hirohashi; Takahiro Nakajima; Tatsuya Kato; Shaf Keshavjee; David Hwang; Brian C Wilson; Gang Zheng; Kazuhiro Yasufuku Journal: Cancer Res Date: 2016-08-19 Impact factor: 12.701